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Background: Breast cancer surgery with axillary lymphadenectomy may be associated with prolonged
stay of the drain in the axilla due to high wound output, which may require further treatments and
prolong the length of stay, impairing quality of life. No deﬁnitive data are available concerning how to
prevent this complication. Our aim was to assess the efﬁcacy of a new low-thrombin ﬁbrin glue in
reducing the serous output from the axillary surgical wound in patients undergoing axillary node
dissection for breast cancer, and its long-term effects on lymphedema. Methods: Sixty patients under-
going surgery between September 2012 and June 2013 were enrolled. Thirty patients received
Artiss®(Baxter, UK) ﬁbrin glue plus drainage, and 30 drainage alone. A multivariate analysis was per-
formed to identify predictors of seroma, and subgroup analyses were performed. Lymphedema was
assessed 12 months after surgery. Results: Patients who received ﬁbrin glue had reduced serum output
collected in the drain after surgery (94.3 ± 22.4 vs 176 ± 24.6 ml p < 0.001) and shorter length of
postoperative hospital stay (p ¼ 0.001). Incidence of seroma at 4-week follow-up did not differ between
groups. At multivariate analysis, BMI 30 kg/m2 was the only independent predictor of seroma forma-
tion (OR ¼ 2.7, 95%CI 1.4e5.3; p ¼ 0.002). Overweight patients receiving Artiss® had fewer seroma at 4-
week follow-up compared with control overweight patients (0% vs 55.6%, p ¼ 0.03). No differences were
observed in lymphedema between groups (6.7% vs 10%, p > 0.99). Conclusions: Low-thrombin ﬁbrin glue
reduced the amount of ﬂuid produced in the axilla after breast surgery. Overweight patients may be the
ideal candidates for this treatment. Such sealant did not increase the rates of lymphedema.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.(R. Benevento), antonio.
@gmail.com (G. Pellino),
dilio@alice.it (G. Candilio),
hotmail.com (F. Selvaggi),
by Elsevier Ltd. All rights reserved1. Introduction
Breast cancer is the most common neoplastic disease in women
worldwide. Axillary lymph node dissection plays an important role
in the surgical management of breast cancer. Despite the trend
toward breast-conserving treatments and the standardization of.
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[1].
The introduction of sentinel lymph node biopsy reduced the rate
of complete axillary lymphadenectomy [2,3], but radical node
dissection still has precise indications and represents a key clinical
problem for the associated postoperative morbidity.
Potential complications are represented by lymphorrhea
requiring delayed drain removal, seroma, hematoma, wound
infection, bleeding and nerve lesion. These lead to patient
discomfort, longer in-hospital stay, prolonged outpatient treat-
ment, and increased costs of care [1e8].
Seroma is reported to occur in 15e81% of patients after node
dissection [4e8]. It can require repeated aspirations and increase
the risk of wound dehiscence, prolonged pain, infection, reduced
limb mobility and prolonged time off-work [7,8], impairing quality
of life. The etiology of seroma relies on extensive axillary lymph
node dissection being responsible for blood and lymphatic oozing
in the residual dead space [9]. Halsted suggested that the obliter-
ation of dead spaces facilitated surgical recovery [10]. Several
strategies have been attempted to reduce seroma, including suction
drainage placement, closure of the axillary fossa by means of
stitches to eliminate “dead spaces”, application of external
compression, and application of ﬁbrin glue [4e6]. However, pro-
longed stay of the drain is a frequent cause of discomfort for the
patients, although needed to avoid the seroma. Fibrin glue offers
several advantages, such as less traumatic closure, reduction of
pain, no need to remove stitches, and excellent esthetic results.
Also, it creates a moist environment and is gradually metabolized
by the surrounding tissue, without generating foreign body
response [9,11].
Nevertheless, the results are not deﬁnitive, and the methodo-
logical and clinical diversity among studies makes it difﬁcult to
draw conclusions [12]. A new ﬁbrin sealant has recently been
introduced, Artiss® (Baxter, UK), characterized by a reduced
thrombin concentration in comparison to other ﬁbrin sealants. This
results in polymerization of Artiss® taking approximately 60 s,
allowing longer time to further manipulate the tissues before ﬁx-
ation, eventually further reducing residual dead spaces.
The purpose of this study was to evaluate the efﬁcacy of low-
thrombin ﬁbrin glue (Artiss®, Baxter, UK) plus suction drain versus
suction drain alone in reducing the serum output after axillary
node dissection in patients with breast cancer, allowing faster
removal of the suction drain without increasing the risk of seroma.
2. Materials and methods
This is a double blind, randomized, controlled clinical trial. All
patients diagnosed with node positive T1eT3 breast cancer can-
didates to surgery with complete axillary lymph node dissection
observed in our Unit between September 2012 and June 2013 were
considered for enrollment in the present study. Patients were
randomized to treatment with ﬁbrin sealant plus a percutaneous
vacuum drain versus percutaneous vacuum drain alone after axil-
lary dissection. Patients were randomized by means of covariate
adaptive randomization [13], meaning that several covariates were
taken into account (age, body mass index [BMI], Eastern Coopera-
tive Oncology Group score [ECOG], and American Society of Anes-
thesiologists score [ASA]) to avoid misbalances between groups.
Surgery was performed by two experienced Senior Surgeons, and
patients were equally distributed between operating teams. Both
patients and surgeons who performed the postoperative assess-
ment were blind to the procedure performed.
Ourprimaryaimwas toobtain a reductionof the serumdischarge
from the axilla collected in the vacuum drain, allowing its removal.
Our secondary aims were to obtain reduction of seroma formation,shorter length of postoperative hospital stay, and similar rates of
lymphedema in the long-term. Approval of the Ethical Committee
wasobtained. All enrolledpatients gavewritten informedconsent to
be included and to complete long-term follow-up.
2.1. Inclusion and exclusion criteria
Inclusion criteria were as follows: female gender, age25 years,
absence of coagulopathy and/or liver disease, BMI 35 kg/m2,
indication to axillary lymph node dissection. All patients candidates
for enrollment underwent preoperative needle biopsy to conﬁrm
diagnosis and CT scan to allow preoperative staging.
Patients who had undergone previous breast surgeries and
those who did not meet inclusion criteria were excluded.
2.2. Intervention and follow-up
Artiss® consists of a dual-chamber pre-ﬁlled syringe that con-
tains in a chamber the solution of coagulable proteins (aprotinin),
in frozen form of 1 ml, 2 ml and 5 ml, and in the other chamber the
thrombin solution (with calcium chloride) in frozen form of 1 ml,
2 ml and 5 ml, allowing to obtain a total volume of 2 ml, 4 ml and
10 ml of the product ready for use. The product is characterized by
lower concentration of thrombin compared with other sealants.
After axillary node dissection, patients were randomly assigned to
either instillation of this low-thrombin ﬁbrin glue and placement of
a vacuum drain (Group A) or placement of vacuum drain alone
(Group B). The former received 4 ml of ﬁbrin glue spray into the
axillary wound cavity before placing stitches.
The amount of serum drained was recorded daily. The total
amount of ﬂuid collected before drain removal and days needed to
remove the drains were used for comparison between groups.
Drains were removed when serum discharge did not exceed 30 ml
during 24 h. Length of postoperative hospital stay was deﬁned as
hours elapsed between surgical procedure and discharge.
Afterdischarge, patientswere followed-up after 1, 2 and4weeks,
undergoing clinical and ultrasonographic exam. Septic and neuro-
logical (pain, paresthesia) complications were recorded. Limb
mobility was always assessed. Neurological pain was assessed by
means of DN4 (Douleur Neuropathique 4) questionnaire [14], con-
sisting of total 10 items grouped in 4 sections: seven items related to
quality of pain (burning, painful cold, electric shocks) and its asso-
ciation to abnormal sensations (tingling, pins and needles, numb-
ness, itching); three items related toneurological examination in the
painful area (touch hypesthesia, pinprick hypesthesia, tactile allo-
dynia). Eachpositive item is scored1whilenegative itemsare scored
0. The total score results from the sumof all 10 items, and the cut-off
value for thediagnosis of neuropathic pain is a total score of 4/10.We
also classiﬁed scores >0 and <4 as “minor disturbances”.
Seroma was assessed 4 weeks postoperatively by means of
ultrasonography.
Lymphedema was assessed 12 months after surgery in all
included patients. Lymphedema was diagnosed and graded as re-
ported by Petrek et al. [15]. Preoperatively we collected baseline
measurements 10 cm above and 5 cm below the olecranon process
on both the treated and contralateral upper extremities. The dif-
ference in measurement at follow-ups at the site of greatest dif-
ference was used to determine extent of lymphedema [16].
Lymphedema was deﬁned as present if difference was >2 cm for
either location.
2.3. Statistical analysis
Data are reported as mean ± standard deviation (SD), unless
otherwise indicated. Continuous variables were analyzed by
Table 2
Results. Data are mean ± SD and n (%).
Variable Group A (n ¼ 30) Group B (n ¼ 30) p
Output drainage, ml 94.3 ± 22.4 176 ± 24.6 <0.001
Time to remove drain, days 2 ± 1.4 4 ± 1.6 0.002
Postoperative hospital stay, hours 50 ± 25.5 98 ± 25.2 0.001
Positive DN4 questionnaire [14] >0.99
Disturbances (4) 0 (0) 0 (0)
Minor disturbances (<4) 1 (3.3) 1 (3.3)
Seromaa 1 (3.3) 6 (20) 0.1
Seromaa in patients  30 kg/m2 0/8 (0) 5/9 (55.6) 0.03
Lymphedemab 2 (6.7) 3 (10) >0.99
Values in bold are p < 0.05.
SD: standard deviation.
a Assessed at 4-week follow-up bymeans of ultrasonographic scan; DN4: Douleur
Neuropathique 4 questionnaire.
b 12 months after surgery.
Fig. 1. Length of postoperative hospital stay in Group A (low-thrombin ﬁbrin glue) vs
Group B (control) patients. Length of postoperative hospital stay was signiﬁcantly
reduced by means of low-thrombin ﬁbrin glue (50 ± 25.5 vs 98 ± 25.2 h, Group A vs
Group B, p ¼ 0.001).
R. Benevento et al. / International Journal of Surgery 12 (2014) 1210e12151212ManneWhitney two-tailed test. Categorical variables were
compared using Fisher's exact test. Values of p < 0.05 were
considered statistically signiﬁcant. A multivariate regression was
performed to identify independent predictors of seroma, and a
subgroup analysis was performed according to variables with
p < 0.01.
In this study we expected a reduction in total amount of drained
ﬂuid (continuous response variable) from independent control and
experimental subjects with 1 control per experimental subject. A
previous study [17] showed a 23% reduction of serous discharge
with ﬁbrin sealant. If the true difference between subjects is 0.23
and 0.3 intergroup SD, 28 patients per group would be required to
reject the null hypothesis that the population means of the
experimental and control groups are equal with power 80% and
Type I error probability of 0.05. We decided to stop enrollment after
reaching at least 30 patients per arm, hypothesizing a 5% detri-
mental effect for the long-term outcome.
3. Results
Sixty patients were enrolled in the present study. Thirty patients
were randomly assigned to Group A (Artiss® þ drain), 30 were
assigned to Group B (drain alone). Age 56.4 ± 11.4 and 57 ± 14.8
years in Group A and B, respectively. Median (range) BMI was 26
(18.6e33.4) kg/m2.
Sixteen patients (26.7%) underwent Madden radical mastec-
tomy and 44 (73.3%) underwent quadrantectomy and ipsilateral
axillary lymph node dissection.
At deﬁnitive pathology, 55 patients (91.7%) had invasive ductal
carcinoma, while 5 (8.3%) had inﬁltrating lobular carcinoma. No
differences between groups were observed in terms of breast
cancer staging, number of resected lymph nodes, lymph node
positivity, and tumor size. Baseline characteristics were homoge-
neous (Table 1).
A suction drainage was always placed and removed after a mean
of 48 h.
Results are depicted in Table 2. The total amount of drained
serum total was 94.3 ± 22.4 vs 176 ± 24.6 ml in experimental and
control group respectively (p < 0.001). The mean time to remove
the drain was signiﬁcantly lower in the Artiss® group (2 ± 1.4 vs
4 ± 1.6 days, Group A vs Group B, p ¼ 0.002).
Length of postoperative hospital stay was signiﬁcantly reduced
by means of low-thrombin ﬁbrin glue (50 ± 25.5 vs 98 ± 25.2 h,
Group A vs Group B, p ¼ 0.001, Table 2, Fig. 1).
Only one patient of Group A developed wound seroma
compared with six of Group B, but difference did not reach statis-
tical signiﬁcance. The former was managed by seroma aspirationTable 1
Characteristics of patients. Data are mean ± SD and n (%).
Variable Group A
(n ¼ 30)
Group B
(n ¼ 30)
p
Age, years 56.4 ± 11.4 57 ± 14.8 0.9
Surgery: 0.8
- Quadrantectomy þ lymphadenectomy 23 (76.7) 21 (70)
- Madden mastectomy 7 (23.3) 9 (30)
Removed lymph nodes on specimen 24 ± 4.6 23.7 ± 5.8 0.5
Pathology: >0.99
- Ductal 27 (90) 28 (93.3)
- Lobular 3 (10) 2 (6.7)
Stage III 7 (23.3) 3 (10) 0.3
ECOG performance status >1 2 (6.7) 1 (3.3) >0.99
ASA score  2 5 (16.7) 4 (13.3) >0.99
BMI, kg/m2 26.2 ± 2.7 26 ± 2.1 0.9
SD: standard deviation; ECOG: Eastern Cooperative Oncology Group; ASA: American
Society of Anesthesiologists; BMI: body mass index.(70 ml) and this was resolved in 5 days. In control group patients
the mean volume of aspirated ﬂuid was 135 ml, and seromas were
resolved within a mean of 12 days.
At multivariate analysis, BMI 30 kg/m2 was the only inde-
pendent predictor of seroma formation at 4th postoperative week
(OR ¼ 2.7, 95%CI 1.4e5.3; p ¼ 0.002). A subgroup analysis showed
that overweight patients receiving Artiss® had fewer seroma for-
mation compared with control overweight patients (0% vs 55.6%,
p ¼ 0.03).
Neither major perioperative complications were observed, nor
were neuropathies or infections.
Group A patients had signiﬁcantly shorter length of post-
operative stay than Group B ones (p ¼ 0.006).
All patients completed long-term follow-up. At 12-month
follow-up, two patients (6.7%) treated with Artiss® had lymphe-
dema, compared with 3 (10%) in the control group (p > 0.99).
4. Discussion
We found low-thrombin ﬁbrin glue able to reduce the output of
serum from the axilla in patients undergoing breast surgery with
lymphadenectomy, allowing earlier drain removal. This signiﬁ-
cantly reduced length of postoperative stay in the hospital. Rates of
seroma at 4-week follow-up formation were lower in patients who
receiving ﬁbrin glue (3.3%) compared with control group (20%), but
this difference was not statistically signiﬁcant. When comparing
overweight patients, we found a signiﬁcant increase in seroma
without low-thrombin ﬁbrin glue (55.6% vs 0%, p ¼ 0.02). No dif-
ferences in neurological pain were observed. Low-thrombin ﬁbrin
glue does not increase the rates of lymphedema in the long-term.
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(ranging between 15 and 81%), and e although it generally resolves
within a fewweeks e it represents a serious problem, especially for
the sequelae stemming from it, namely prolonged hospital stay and
increased patient discomfort [7,18].
Seroma is deﬁned as the accumulation of lymph below the skin
surface and at the level of the axilla area of lymphadenectomy
[19e21]. Both pathogenesis and ideal techniques to prevent seroma
formation still remain unclear [22].
Many procedures are reported in the literature that could help
in lowering its incidence, such as insertion of a suction drainage in
the axilla [23], external compression bandages [24], using har-
monic scalpel for dissection [25]. Attention has been also paid to
the implementation of various surgical techniques aimed to reduce
the postoperative dead space in the axilla [26,27], among which
ﬁbrin glue plays a key role [28,29].
Controversy exists in the literature concerning the timing of
drainage removal from the axilla. In common practice, the drainage
is kept in place until the amount of serum in the 24 h is  50 ml, an
event that may require sometimes even up to 10 days [30]. In our
practice, we use to remove the drain when the serum drained does
not exceed 30 ml in 24 h.
Some authors report the use of multiple drainages [31], others
have studied the effects of drainage by gravity and vacuum, but in
both cases, the beneﬁt did not meet the expectations [32].
Divino et al. [33] reported a 6% incidence of seroma for patients
with drainage, compared to 40% for patients without. Somers et al.
[3] compared patients who received the drainage with those who
did not and found a higher incidence of seroma in the latter group.
On the contrary, Porter [34] reported no statistically signiﬁcant
differences in rates of seroma between patients with drainage (73%)
compared with those without (89%).
Many studies showed that there is no relation between how
long the drain is kept and likeliness of developing seroma,
happening in 15e83% of patients, even if drainage is removed after
several days [2e6]. In the present study the incidence of seroma
after the removal of drainage was 20% in the control group and 3.3%
in the group treated with Artiss®, but the difference was not sta-
tistically signiﬁcant.
There are no standardized procedures to prevent the formation
of seroma yet.
It may be speculated that seroma formation can bemainly due to
the oozing of small vessels, blood and lymph vessels, and to the
formation of a cavity, the so-called postoperative dead space, caused
by the removal of the tissue. An effective surgical adhesive could not
only improve hemostasis by reducing the oozing blood [35], but also
reduce if not prevent the continued loss of lymph from small
lymphatic vessels, by allowing a greater adhesion between tissues,
eventually leading to less postoperative complications [18].
Thehypothesiswouldbesupportedbytheabsenceofﬁbrinogen in
the serum fromthedrainage of thepatients, therefore suggesting that
the addition of ﬁbrin would reduce the formation of seroma [36,37].
Fibrin glue interacts with the damaged tissues during surgical pro-
cedures, encouraging the growth of ﬁbroblasts and wounds healing
[4]. It accelerates the mechanisms of coagulation, promoting hemo-
stasis so as to prevent the formation of hematomas, which delay the
process of surgical recover. Fibrin also seals the lymphatic vessels,
causing a consequent reduced seroma formation, and reduces post-
operative dead space by favoring tissue adhesion [4,35e39]. Fibrin
glue has also been reported to be useful in ensuring optimal place-
ment of prosthetic materials, reducing postoperative pain [35,38,39].
Several studies compared the effects of ﬁbrin glue after axillary
lymphadenectomy [5,11]. Ruggiero et al. [5] assigned 90 patients
receiving quadrantectomy or mastectomy and axillary node
dissection to treatment with ﬁbrin glue plus drainage (45 patients)or with drainage alone (45 patients), and found that ﬁbrin glue did
not always prevent seroma formation, even if it may reduce seroma
magnitude and duration. A previous meta-analysis [11] of eleven
randomized trials showed that ﬁbrin sealant after breast surgery
did not reduce the rate of postoperative seroma (RR 1.14), the vol-
ume of drainage (weighted mean difference e 117.7), or the length
of stay (weighted mean difference e 0.38). The authors concluded
that the available evidences did not support the use of ﬁbrin sealant
in breast cancer surgery to reduce postoperative drainage or
seroma formation [11]. However, they also found that most trials
were small and of poor methodological quality.
Lymphedema is potentially the most debilitating long-term
complication after axillary surgery. Its true incidence is difﬁcult to
determine, as methods used for assessing lymphedema are un-
standardized. When considering good quality assessment of such
complication [15,16], the rates of lymphedema after axillary
dissection are as high as 16% at 5-year follow-up [16], reaching up
to 49% in the long-term [15]. Interestingly, lymphedema can occur
also after sentinel lymph node biopsy without dissection in
approximately 5% of patients [16]. We assessed the long-term
consequences of a low-thrombin ﬁbrin glue on lymphedema risk,
andwewere able to demonstrate that this sealant does not increase
the rates of such an unpleasant complication. It could also be
offered to patients receiving sentinel lymph node biopsy alone,
when they have risk factors for developing lymphedema.
Although controversial results are reported in the literature, the
use of ﬁbrin glue associated with a suction drainage in the axilla
may be a viable alternative in breast cancer surgery, both to reduce
the amount of serum and the duration of the drain stay, ultimately
reducing days off-work. When analyzing our results, one should
however consider that factors other than axillary ﬂuid drainage
might have determined the length of postoperative stay in the
hospital, i.e. social factors and the availability of transport as well as
the extent of the surgical intervention (two more patients had a
Madden mastectomy in Group B than in group A). This should be
posed into perspective. Nevertheless, in our series no major com-
plications occurred, and patients characteristics were similar be-
tween groups. Moreover, evidences are growing from breast as well
as different surgical specialties supporting the hypothesis that
serum discharge and subsequent seroma formation may prolong
postoperative hospital stay by increasing wound related compli-
cations, and eventually inﬂuencing patients' quality of life
[2e6,40e42]. Provided no signiﬁcant differences are observed be-
tween patients which may inﬂuence length of postoperative stay,
the serum output can play a primary role.
Our study aimed to evaluate the efﬁcacy of a newﬁbrin sealant in
decreasing the axillary output and postoperative seroma formation
in patients operated on for breast cancer, with breast-conserving
surgery or radical surgery. Unlikely previous agents used for
similar studies, Artiss®, made from pooled human plasma, has a
reduced concentration of thrombin in comparison to other ﬁbrin
sealants used as an adjunct to hemostasis. Artiss® is not indicated as
an adjunct to hemostasis. Due to lower thrombin concentration,
polymerization of this such ﬁbrin glue takes approximately 60 s,
allowing for time to further manipulate the tissues prior to their
adherence and ﬁxation [43]. Artiss® promotes adhesion/sealing of
the subcutaneous tissues in plastic and reconstructive surgery, and
in burn surgery, as an adjuvant or in addition to sutures or staples.
Artiss® use signiﬁcantly reduces the volume of drainage by elimi-
nating dead space trough improved ﬂap adherences [44].
5. Conclusions
In our study we found that low-thrombin ﬁbrin glue reduced
the amount of ﬂuid produced in the axilla after breast surgery,
R. Benevento et al. / International Journal of Surgery 12 (2014) 1210e12151214allowing earlier removal of the drain even reducing the risk of
seroma. Overweight patients may be the ideal candidates to low-
thrombin ﬁbrin glue placement. Further studies are needed to
clarify the mechanisms underlying seroma formation, but low-
thrombin ﬁbrin glue is likely to represent a useful tool to prevent
it. Patients receiving such sealant were not at higher risk of
developing long-term lymphedema.
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